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Background and objectives: The diagnosis of acute kidney injury (AKI) is usually based on changes in serum creatinine,
which is a poor marker of early renal dysfunction. The discriminative and predictive abilities of serum and urinary cystatin
C were examined for the prediction of AKI.
Design, setting, participants, & measurements: In this prospective cohort study, serum and urinary cystatin C were serially
measured in a heterogeneous group of patients (n  616) presenting to a tertiary care emergency department. The primary
outcome was AKI, classified according to RIFLE and AKIN criteria. The secondary outcome was an adjudication based on
clinical criteria to AKI, prerenal azotemia, chronic kidney disease (CKD), and normal kidney function.
Results: Patients were adjudicated to have AKI in 21.1%, prerenal azotemia in 25.8%, CKD in 2.4%, and normal kidney
function in 50.7%. For the diagnosis of AKI, the discriminatory ability of urinary creatinine and cystatin C was marginal. Both
serum cystatin C and serum creatinine (at presentation and 6 hours later) showed high discriminatory ability for the diagnosis
of AKI. However, only serum cystatin C attained a significant early predictive power (Hosmer-Lemeshow P value > 0.05).
Serum cystatin C could differentiate between AKI and prerenal azotemia, but not between AKI and CKD.
Conclusions: Serum cystatin C is an early, predictive biomarker of AKI, which outperforms serum creatinine in the
heterogeneous emergency department setting. However, neither biomarker discriminated between AKI and CKD. Additional
biomarkers continue to be needed for improved specificity in the diagnosis of community-acquired AKI.
Clin J Am Soc Nephrol 5: 1745–1754, 2010. doi: 10.2215/CJN.00690110
T he incidence of acute kidney injury (AKI) is increasingglobally, affecting about 6% of all hospitalized patientsin whom it is an independent predictor of mortality
and morbidity (1). Much is now known about the epidemiology
of AKI in the hospital-acquired and critical care settings (2).
AKI occurring in a community setting is also common but quite
distinct, and published data are scarce. Community-acquired
renal dysfunction encountered in the emergency department
(ED) is frequently caused by volume depletion, whereas hos-
pital-acquired AKI often accompanies other organ disease pro-
cesses and complicates their management and outcomes (3). In
the ED, the clinician’s priorities are (1) to detect AKI early so
that preventive and therapeutic approaches may be imple-
mented in a timely manner, and (2) to differentiate between
prerenal azotemia (preR), chronic kidney disease (CKD), and
intrinsic AKI. Unfortunately, neither is possible with serum
creatinine (SCr) measurements, since changes in SCr lag behind
both renal injury and renal recovery, and are influenced by
several nonrenal factors (4,5).
A number of novel plasma and urinary biomarkers have
recently been proposed for the early diagnosis of AKI and its
clinical outcomes in a variety of clinical settings (6,7). Among
these, cystatin C appears to be a useful detection marker for
AKI (8). It is a low molecular weight cysteine proteinase that is
stably produced by all nucleated cells in a constitutive fashion.
It is freely filtered by the renal glomeruli and totally reabsorbed
in the proximal tubule, without secretion. Serum concentration
of cystatin C is thus determined primarily by GFR. Cystatin C
is not normally found in urine in significant amounts (9). Ele-
vated urinary levels of cystatin C may reflect tubular dysfunc-
tion independent of GFR (10,11) and may provide an early
indication of AKI in the cardiac surgery (12) and critically ill
(13) patients. Multiple studies evaluating serum cystatin C
(SCysC) as a GFR marker have shown that it performs at least
as well as SCr in the population at large, and it is superior to
SCr in specific patient populations (14). SCysC has also been
proposed as an early biomarker of AKI in the intensive care
(15,16), cardiac surgery (17), and radiocontrast administration
(18) settings.
The aim of this prospective cohort study was to evaluate the
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accuracy of SCysC and urinary cystatin C (UCysC) as early
biomarkers of AKI in an unselected, heterogeneous group of
patients admitted to the ED in a large tertiary care hospital. The
primary end point was a diagnosis of AKI fulfilling the SCr-
based RIFLE (19) and AKIN (20) criteria. The secondary end
point was the differentiation between preR, intrinsic AKI, and
CKD at the time of presentation to the ED.
Materials and Methods
Patient Population
Patients admitted to the nonsurgical ED of the Fernando Fonseca
Hospital from March to November 2008 were enrolled in a consecutive
manner after informed consent was obtained. Exclusion criteria were:
age under 18 years or over 80 years of age, complete anuria, established
CKD stage 4 or greater (21), urinary obstruction, cytotoxic therapy, and
patients predicted to be admitted for less than the 48-hour sample
collection period.
Biomarker Measurements
The baseline renal function using SCr was obtained from the Fer-
nando Fonseca Hospital electronic records, for 1 to 6 months before
admission. A prospective renal function assessment was carried out by
measuring SCr, urinary creatinine (UCr), SCysC, and UCysC. Serial
blood and urine samples were obtained at 0, 6, 12, 24, and 48 hours
from presentation to the ED (Figure 1). After transfer to the medical
unit, SCr was followed until hospital discharge. Creatinine was mea-
sured in plasma and urine by modified Jaffe kinetic reaction. Cystatin
C was measured in plasma and urine by particle-enhanced immunon-
ephelometry (BN Systems, Dade-Behring, Marburg, Germany) with N
latex Cystatin C assay (22).
Clinical Adjudication
GFR was estimated by using the Modification of Diet and Renal
Disease formula (23). On the basis of baseline and prospective mea-
surements of SCr, all patients were adjudicated to one of four diagnos-
tic categories: Normal kidney function (NF), nonprogressive CKD,
preR, or AKI. This renal function classification was performed in con-
sensus by the nephrologists of the study group who were blinded to the
biomarker results, as described previously (24). All classifications were
subsequently independently verified by three nephrologists who were
blind to the study and belonged to the Nephrology staff of three other
hospitals in Lisbon. NF was defined as a baseline estimated GFR
(eGFR) 60 ml/min per 1.73 m2 and no increase in SCr during the
hospitalization. Nonprogressive CKD was defined as a sustained and
unchanging decrease in GFR that met criteria for CKD (eGFR 60
ml/min per 1.73 m2) and persisted for more than 3 months before
admission (21). preR was defined as a new-onset increase in SCr that
resolved within 48 hours and returned to the baseline NF level. AKI
was defined according to the RIFLE criteria (19) and modified accord-
ing to AKIN criteria (20) with new-onset of at least 1.5-fold increase or
0.3 mg increment of SCr values from baseline, sustained for more
than 48 hours.
To analyze factors that predispose to AKI, nature and timing of the
inciting event, and the response of the kidney to the insult, variables
included in the “Multidimensional Criteria” (25) were recorded, includ-
ing “susceptibility” (pre-existing kidney disease and risk of developing
acute injury), nature and timing of the “insult” on the basis of the
specific insult and the time interval from the insult to the point of
evaluation (in this case the admission to the ED), “response” corre-
sponding to the RIFLE classification, and nonrenal organ dysfunction.
Statistical Analysis
Categorical data were presented as frequencies and percentages, and
continuous variables as mean or median, SD or interquartile range
(25th percentile to 75th percentile). Nonparametric (2, Mann-Whitney
U, and Kruskall-Wallis) tests were used because of the existence of
outliers, high variability, and skewed distributions. The 95% confidence
intervals (CI) were also calculated whenever appropriate.
The logistic regression model was fitted to the data not only to
determine the influence of each of the studied variables on the risk of
AKI but also to study the ability of the models to predict AKI (by the
Hosmer-Lemeshow goodness-of-fit test and calibration plots) and to
discriminate between those patients who will develop AKI from those
who will not (by the area under the receiver operating characteristic or
ROC curve). A value of 0.50 is obtained when a model discriminates no
better than chance, and a value of 1.0 means perfect accuracy (26). The
Hosmer-Lemeshow test compares observed and expected frequencies
of AKI patients based on the values of the estimated probabilities
obtained by the logistic regression model (27). In this test, a high P
value indicates that the model is performing well, i.e., there is not a
large discrepancy between observed and expected AKI.
Generalized Additive Models (GAMs), for binary response, were
used to calculate cut-off points for SCr and cystatin C. To assess the
performance of those diagnostic tests, sensitivity, specificity, and pos-
itive and negative predictive values (PPV and NPV) were calculated as
well as the likelihood ratios, which incorporates both the sensitivity
and specificity of the test and provides a direct estimate of how much
a test result will change the odds of having AKI.
The significance level   5% was considered. All data were ana-
Figure 1. Study flow diagram. Patients hospitalized following presentation to the emergency room (ER) were included if they met
the eligibility criteria. SCr, UCr, SCysC, and UCysC were measured during the hospitalization, at the indicated times, until
discharge (D). At the end of the study, patients were adjudicated as having AKI, preR, CKD, or NF.
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lyzed using the Statistical Package for the Social Sciences for Windows
15.0 (SPSS, Inc.), the S-PLUS 6.0 (Insightful Corp.) package, and Inter-
cooled Stata 9.2 for Windows (StataCorp LP, USA).
Results
Patient Characteristics
A total of 800 patients were enrolled, but 172 were excluded
because they met one or more exclusion criteria, and an addi-
tional 12 declined to continue with their participation. In total,
616 subjects consented and completed the protocol with a mean
age of 59.1 years (95% CI: 57.9 to 60.3). As listed in Table 1, 130
patients (21.1%) met AKI criteria, 159 (25.8%) had preR, 15
(2.4%) had stable CKD, and 312 (50.7%) had NF. In the AKI
group, 44 subjects (34%) had pre-existing CKD. Patient charac-
teristics by diagnostic classification are indicated in Table 1.
Patients diagnosed as AKI and CKD were significantly older
than those with a diagnosis of preR and patients with NF (P 
0.001).
On the basis of retrospective analysis of renal function and
associated diseases, all patients were assigned to susceptibility
stages I to IV (25). By this analysis, 67.2% of patients were in
stage I; 21.4% in stage II; 4.9% in stage III; and 6.5% in stage IV.
Majority of subjects assigned to the two last stages corre-
sponded to AKI patients (63.3% for stage III and 62.5% for stage
IV). Decreased renal perfusion was the principal clinical con-
dition that caused AKI (66.2%: n  86). Almost 77% (100) of the
patients with AKI were classified as stage 1 by AKIN criteria,
corresponding to a large proportion of patients classified as
“Risk” by RIFLE criteria. Six patients (1%) needed renal re-
placement therapy, and 27 died (15 in the AKI group).
Previous baseline SCr values were not available for only 2.4%
of the patients. In these subjects, baseline renal function was
calculated using previously published formulas (19). Further-
more, these values were confirmed after 1 year of follow-up.
None of the subjects without previous baseline SCr was classi-
fied as having AKI.
Differential Diagnosis
The highest concentrations of SCr and SCysC were noted in
patients who developed AKI (median 1.6 mg/dl and 1.4 mg/dl,
respectively, at baseline), as shown in Table 1 and Figure 2. On
average, patients with preR, stable CKD, or NF had signifi-
cantly lower concentrations of SCysC and SCr, as shown in
Table 1 and Figure 3. In terms of urinary measurements, the
median values of the UCysC /Cr ratio were similar in all
groups. There was a significant difference only between AKI
patients and those with NF (P  0.001).
Figure 2. Pattern of biomarkers in AKI and non-AKI patients
over time. (A) SCr. (B) SCysC. Mean values are displayed with
error bars representing SD.
Figure 3. Distribution of biomarker values by diagnostic group. Scatter plots of SCysC, SCr, and UCysC/Cr ratio. Within each
group, i.e., AKI, preR, CKD, or NF, values are shown for each of the serially measured time points. Both SCysC and SCr could
discriminate AKI from preR and NF (P  0.001). UCystC/Cr could discriminate AKI from NF (P  0.001).
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When AKI patients were compared with the other three
groups combined (preR, CKD, and NF), all biomarkers (SCr,
SCysC, and UCysC/Cr ratio) showed greater levels in patients
with AKI than those without (P  0.001), as shown in Figure 3.
Both SCr and SCysC concentrations were noted to be increased
at baseline in patients who were subsequently adjudicated to
have AKI. The pattern of the UCysC/Cr ratio was quite differ-
ent, with highest levels at baseline (median 0.49 mg/g) and
decreasing over 48 hours (0.28 mg/g). Therefore it was not a
sustained diagnostic marker of AKI.
Predictive and Discriminative Ability for the Diagnosis of
AKI
ROC curves were generated at all time points for all biomar-
kers, to test the ability to detect AKI. The results are listed in
Table 2. UCysC, UCr, and UCysC/Cr ratios were not useful
predictors of development of AKI, with low values for the areas
under the ROC curve (AUC-ROC). In contrast, the AUC-ROC
was greater than 0.86 for SCysC and greater than 0.88 for SCr at
all five study points, indicating excellent discriminatory ability
for the early diagnosis of AKI (all P 0.001), as shown in Table 2
and represented in Figure 4. There were no differences between
the ROC curves for SCysC and SCr at the critical first two time
points of the study (P  0.288 and P  0.141 for the initial
presentation and 6-hour time points, respectively). However,
the model with SCysC was particularly well-calibrated with
high Hosmer-Lemeshow P values of 0.667, 0.080, 0.463, 0.502,
and 0.504 for each of the five time points examined, indicating
no evidence of lack of fit. Furthermore, the observed event rates
appeared close to predicted event rates when plotted across
possible point probabilities, as shown in Figure 5. On the con-
trary, a significantly lower value for the Hosmer-Lemeshow P
Table 2. Predictive and discriminative ability of all biomarkers at different time points
Biomarker AUC 95% CI P Value Hosmer-Lemeshow P Value
Serum
Cr
T0 0.88 0.85 to 0.92 0.001 0.001
T6 0.9 0.86 to 0.93 0.001 0.053
T12 0.9 0.87 to 0.94 0.001 0.095
T24 0.92 0.89 to 0.94 0.001 0.012
T48 0.92 0.90 to 0.95 0.001 0.032
CysC
T0 0.87 0.83 to 0.90 0.001 0.667
T6 0.87 0.83 to 0.91 0.001 0.080
T12 0.88 0.84 to 0.91 0.001 0.463
T24 0.86 0.82 to 0.90 0.001 0.502
T48 0.87 0.83 to 0.91 0.001 0.504
Urinary
Cr
T0 0.59 0.53 to 0.65 0.003
T6 0.62 0.56 to 0.67 0.001
T12 0.58 0.52 to 0.63 0.01
T24 0.6 0.54 to 0.65 0.002
T48 0.54 0.49 to 0.60 0.163
CysC
T0 0.57 0.51 to 0.62 0.032
T6 0.59 0.53 to 0.64 0.005
T12 0.59 0.53 to 0.65 0.003
T24 0.59 0.54 to 0.65 0.002
T48 0.61 0.55 to 0.67 0.001
CysC/Cr
T0 0.61 0.55 to 0.67 0.001 0.026
T6 0.65 0.59 to 0.71 0.001 0.011
T12 0.61 0.56 to 0.67 0.001 0.003
T24 0.64 0.58 to 0.70 0.001 0.023
T48 0.59 0.53 to 0.65 0.005 0.061
Predictive and discriminative ability of SCysC, SCr, UCr, and UCysC/Cr ratio. AUC, area under the ROC curve; CI,
confidence intervals. Hosmer-Lemeshow (HLS) P value not calculated for UCr and UCysC due to low AUC values; HLS
considered significant when P value  0.05.
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value for SCr indicated an inferior performance of this marker
with respect to AKI prediction. Thus, SCysC could predict the
evolution to AKI more accurately than SCr. In terms of the
UCysC/Cr ratio, in addition to the low discriminative power,
the P values for Hosmer-Lemeshow test were also not accept-
able for a good test, as shown in Table 2.
Test Performances
To achieve a more detailed analysis of our data, we applied
GAMs. As shown in Figure 6, the shape of the SCr and SCysC
curves were similar. Thus, when the SCr or SCysC values were
rising, there was a higher risk of developing AKI. The cut-off
points were calculated based on the estimated functions ob-
tained through a binary response GAM. The cut-off points at
the different study times were 0.98 mg/L for SCysC (Figure
6B), 1.04 mg/100 ml for SCr (Figure 6A), and 0.46 mg/g creat-
inine for UCysC/Cr ratio.
Performance measures of SCr, SCysC, and UCysC/Cr ratio
as AKI biomarkers were validated by calculating sensitivity,
specificity, PPV, and NPV, as well as likelihood ratios (LR
and LR-). All values are shown in Table 3. SCr and SCysC had
a high sensitivity as biomarkers of AKI, but moderate specific-
ity. Both markers had excellent NPV, but borderline PPV. The
likelihood ratio values showed that both markers had little
effect on the probabilities (odds) of AKI, as none was greater
than five or close to zero. Thus, a positive SCysC level did not
have strong correlation with AKI, but a negative SCysC level
was strongly associated with the absence of AKI at cut-off
values calculated by GAMs.
Severity Stratification
Box plots for SCysC, SCr, and UCysC/Cr levels stratified by
each AKIN grade are shown in Figure 7. The SCysC concen-
trations rose significantly according to the severity of AKI
(median values 0.78, 1.3, 1.53, and 2.13, corresponding to no
AKI, and AKIN stages 1 through 3). UCysC/Cr ratios only rose
at stage 3 of AKIN classification. Similarly, when SCysC was
stratified according to RIFLE classification, its increasing levels
accompanied the increment in severity of AKI (not shown).
Discussion
Hospital acquired AKI is distinct from the community acquired
variety, and the incidence and outcomes of the latter still remain
unclear. In our study, 21% of the patients enrolled had AKI in
evolution at the time of admission, and 25.8% presented with
preR. The majority of these patients already had decreased renal
function as shown by the median values of SCr and SCysC at
admission, indicating that the insult had already occurred. The
renal injury had begun 24 to 48 hours before admission in the
majority of cases, and more than half of established AKI were
due to decreased renal perfusion. These medical conditions
would likely be reversible if treated promptly, which would
Figure 4. ROC curve of SCysC, SCr, and UCysC/Cr ratio as
markers to AKI diagnosis. (A) At T0 and (B) at T6.
Figure 5. Calibration plots: Predicted risk of AKI versus ob-
served AKI rate at T0 for SCysC (A) and SCr (B).
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require an accurate diagnosis having been made earlier and
discriminating AKI from preR.
The diagnostic approach to AKI in emergency settings still
rests on BUN and creatinine, despite being insensitive, nonspe-
cific, and delayed. We hypothesized that SCysC would mark
AKI more accurately than SCr in a heterogeneous sample of
patients presenting to our nonsurgical ED. Our results indicate
that both SCysC and SCr differentiated between patients with
AKI and those without AKI (P  0.001). Moreover, we demon-
strated that SCysC distinguished AKI from preR, which is a
major dilemma for early therapeutic approaches in the emer-
gency settings, since SCr measurements typically cannot make
this distinction (24). However, the most significant result was
the excellent power of SCysC for predicting AKI even in the
early time points (at presentation and at 6 hours), with AUC
values greater than 0.87. Surprisingly, these AUC values are
comparable to those for SCr, the current standard marker for
AKI. However, the calibration of the model of SCysC at all
study time points showed no evidence of lack of fit, indicating
that all observed events were similar to those predicted. In
contrast, the significant lack of fit for SCr indicated a relatively
poor performance for this biomarker with regard to prediction
of AKI.
Many recent studies have explored improvements in the
early diagnosis of AKI (6,7). The majority of those studies have
focused on hospital-acquired AKI. We have demonstrated in a
prospective manner that community-acquired renal dysfunc-
tion at presentation to the ED is strongly associated with in-
creased SCysC but not with UCysC. Our results do not permit
us to identify how early in the course of the disease does SCysC
detect AKI, because patients with this diagnosis at admission
time already had acute renal dysfunction. In a recent study of
patients presenting to an ED, the performance of SCr showed
high discriminative capacity and performance for AKI (24).
However, the event rate was very small, with only 30 patients
(4.7%) developing AKI. Furthermore, the mean SCr at admis-
sion was much higher (5.6 mg/dl), with greater percentage of
patients needing dialysis when compared with the present
study. In our study, we have shown in a broad spectrum of
patients that SCysC performs better than SCr as an AKI marker.
In addition, we demonstrated that SCysC level increased with
the severity of AKI. We have not been able to analyze important
AKI outcomes such as predicting dialysis requirement or in-
hospital death, since these event rates were very small.
This study has important limitations. First, we used SCr as
the (flawed) gold standard for the definition of AKI. Second,
the degree of renal dysfunction in our cohort of AKI patients
was moderate at best, with medium values of SCr of 0.95 mg/dl
and only 1% of subjects needing dialysis. Third, it is a single
center study, so our results must be validated in larger multi-
center studies. Fourth, we excluded patients with CKD stage 4
to 5, which could potentially explain the lower rate of CKD in
our cohort. Fifth, SCysC may be influenced by a number of
nonrenal factors, including large doses of corticosteroids, thy-
roid dysfunction, systemic inflammation, neoplasia, age, type
of assay used, and even to some extent by muscle mass (28).
In summary, SCysC is an excellent early biomarker for the
diagnosis of AKI in the unselected ED setting. Surprisingly, this
biomarker also reliably differentiates AKI from preR. The
global availability of standardized clinical platforms for the
measurement of SCysC (22,29), as well as other promising AKI
biomarkers such as neutrophil gelatinase-associated lipocalin
(24,30–32) that indicate structural renal injury, potentially bring
us closer to a personalized and predictive approach to the
diagnosis and management of community-acquired AKI. It is
hoped that early identification of intrinsic AKI in the ED setting
will allow for risk stratification, disposition planning, and pro-
spective testing of promising interventions that have been ef-
fective in preventing and ameliorating AKI in experimental
models if instituted early during the course of the injury (33).
Figure 6. Estimated functions by the fitted GAMs considering
SCr (A) and SCysC (B) as the only covariate at T0.
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